Antibiotic medication – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:53 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Antibiotic medication – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Doxorubicin Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-doxorubicin-market-2021-2025/ Tue, 08 Jun 2021 05:57:09 +0000 https://www.cri-report.com/?post_type=product&p=11771 In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the growth rate of Doxorubicin’s sales value in the Chinese market has declined, but the sales still reached about CNY 1 billion in 2020.

The post Investigation Report on China’s Doxorubicin Market 2021-2025 first appeared on CRI Report.

]]> Doxorubicin belongs to the anthracycline class (Anthracycline) antibiotics, which can inhibit the synthesis of RNA and DNA. It has a strong inhibitory effect on RNA and has a broad anti-tumor spectrum. It has an effect on a variety of tumors. Doxorubicin was developed by Alza Corporation of the United States. According to CRI’s market research, as of the end of 2020, the original Doxorubicin drug has not been listed in China, but many companies have obtained approval for the listing of generic drugs in China and have been included in the China National Medical Insurance Category A catalog. By 2020, there were 8 manufacturers in the Chinese Doxorubicin market, of which CSPC Ouyi Pharmaceutical Co., Ltd. was the main manufacturer.

According to CRI’s market research, the sales value of Doxorubicin in the Chinese market has increased year by year from 2016 to 2020. Especially, the sales of Doxorubicin in the Chinese market reached CNY 855 million in 2019, a year-on-year increase of 69.75%. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the growth rate of Doxorubicin’s sales value in the Chinese market has declined, but the sales still reached about CNY 1 billion in 2020. The CAGR of Doxorubicin’s sales value in the Chinese market is 38.60% from 2016 to 2020.

CRI expects that with the increase of cancer patients in 2021-2025, the sales volume of Doxorubicin in the Chinese market will increase steadily. Doxorubicin liposome injection has the advantages of targeting, sustained release, and reduced toxicity. Based on these advantages, the sales volume and sales of Doxorubicin liposome injection will continue to increase. In addition, the alleviation of the COVID-19 epidemic will also cause the sales of Doxorubicin to show a recovery growth.

Topics Covered:
-The impact of COVID-19 on China’s Doxorubicin market
– Sales value of China’s Doxorubicin 2016-2020
– Competitive landscape of China’s Doxorubicin market
– Prices of Doxorubicin in China
– Prices of Doxorubicin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Doxorubicin market
– Prospect of China’s Doxorubicin market from 2021 to 2025

The post Investigation Report on China’s Doxorubicin Market 2021-2025 first appeared on CRI Report.

]]> Investigation Report on China’s Levofloxacin Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-levofloxacin-market-2021-2025/ Tue, 08 Jun 2021 05:57:05 +0000 https://www.cri-report.com/?post_type=product&p=11770 Due to the impact of the COVID-19 epidemic on the overall medical diagnosis and treatment services, sales value of Levofloxacin in the Chinese market decreased to CNY 1.01 billion in 2020

The post Investigation Report on China’s Levofloxacin Market 2021-2025 first appeared on CRI Report.

]]> Levofloxacin, developed by Daiichi Sankyo, is used to treat bacterial infectious diseases such as community pneumonia, sinusitis, urinary tract infections. Levofloxacin tablets were approved in China in 1995, and Levofloxacin injection and oral regular-release liquids have entered China’s medical insurance. By the half-past of 2021, there are many manufacturers in China’s Levofloxacin market, among which Daiichi Sankyo Pharmaceutical (Beijing) accounts for the highest proportion of market share.
According to CRI’s market research, the sales value of Levofloxacin in the Chinese market from 2016 to 2019 has shown an overall upward trend. Due to the impact of the COVID-19 epidemic on the overall medical diagnosis and treatment services, the sales value of Levofloxacin in the Chinese market decreased to CNY 1.01 billion in 2020, with a year-on-year decrease of 28.23%. The CAGR of the sales value of Levofloxacin in the Chinese market is -4.75% from 2016 to 2020.
CRI expects that with the relief of the COVID-19 epidemic, the sales of Levofloxacin will have a restorative growth from 2021 to 2025. In addition, Levofloxacin has a broad antibacterial spectrum, strong antibacterial activity, high bioavailability, and good tissue cell permeability. Based on these advantages, the sales of Levofloxacin will grow steadily in the future. Further, the sales and sales volume of Levofloxacin used to treat bacterial infection will grow with the popularization and improvement of China’s medical and health services.

Topics Covered:
-The impact of COVID-19 on China’s Levofloxacin market
– Sales value of China’s Levofloxacin 2016-2020
– Competitive landscape of China’s Levofloxacin market
– Prices of Levofloxacin in China
– Prices of Levofloxacin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Levofloxacin market
– Prospect of China’s Levofloxacin market from 2021 to 2025

The post Investigation Report on China’s Levofloxacin Market 2021-2025 first appeared on CRI Report.

]]>